InvestorsHub Logo
Followers 94
Posts 11326
Boards Moderated 0
Alias Born 11/02/2003

Re: ecmorgan post# 12491

Monday, 11/15/2004 3:38:07 PM

Monday, November 15, 2004 3:38:07 PM

Post# of 64738
This is interesting CYGX is conducting a pilot studies for several companies ? Wow that sounds good.



Genomics field has expanded the number of potential drug targets to several thousand. The CytoGenix proprietary gene down-regulation system is a powerful tool in confirming gene target function. In July 2002, we inaugurated a service geared towards assisting pharmaceutical and biotech companies improve drug discovery efficiency. In addition to our work on in-house targets, we are conducting a pilot studies for several companies. For a fixed fee, we will knockdown a gene in a cell system. This will confirm the gene's relevance to the disease of interest. Those genes found to be highly disease-related become targets for new drug or molecular therapies
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.